P08.17 Mitotic checkpoint inhibition augments Tumor-Treating-Field (TTField) effects on glioblastoma cells

di Kessler, A. F.
Pubblicato in Neuro Oncol (2017)

P09.21 Complete radiological response after subtotal resection in two Gglioblastoma patients treated with Tumor Treating Fields

di Kessler, A. F., Linsenmann, T.
Pubblicato in Neuro Oncol (2017)

P14.59 Post-Market Surveillance Data of the EMEA region indicate good tolerability of TTFields in WHO Grade III Glioma

di Keßler, A F, Ritz, R
Pubblicato in Neuro Oncol (2019)

P06.06 Is activating transcription factor 5 (ATF5) a new therapeutic target in astrocytomas of different WHO grades and varying biological behavior? An expression analysis

di Feldheim, J. A., Keßler, A. F.
Pubblicato in Neuro Oncol (2016)

P08.20 Augmentation of Tumor-Treating-Field (TTField) effects on glioblastoma cells by mitotic checkpoint inhibition

di Frömbling, G. E., Kessler, A. F.
Pubblicato in Neuro Oncol (2016)

P14.60 FET PET response upon radiochemotherapy followed by Tumor Treating Fields (TTFields) in a patient with progressive high-grade glioma

di Keßler, A F, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M
Pubblicato in Neuro Oncol (2019)

P14.28 First report on the combination of axitinib and Tumor Treating Fields (TTFields) in three patients with recurrent glioblastoma

di Keßler, A F, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M
Pubblicato in Neuro Oncol (2019)

O4.06 ANALYSIS OF RAF PROTEINS IN MALIGNANT GLIOMAS

di Hagemann, C., Gloger, J., Kessler, A.F., Linsenmann, T., Vince, G.H., Ernestus, R., Löhr, M.
Pubblicazione 2014

P04.33 Effects of Tumor Treating Fields (TTFields) on blood brain barrier (BBB) permeability

di Kessler, A F, Schaeffer, C, Burek, M, Ruschig, U, Ernestus, R, Löhr, M, Förster, C, Hagemann, C
Pubblicato in Neuro Oncol (2018)

P01.13 EXPRESSION OF HUMAN ENDOGENOUS RETROVIRUS K (HERV-K) IN HUMAN ASTROCYTIC TUMORS

di Kessler, A.F., Wiesner, M., Denner, J., Kämmerer, U., Löhr, M., Linsenmann, T., Vince, G.H., Ernestus, R., Hagemann, C.
Pubblicazione 2014

OS4.3 The BReMen trial: Patients with benign meningioma - is rehabilitation really necessary?

di Kessler, A F, Krause, K, Al-Shameri, B, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M, Jentschke, E
Pubblicato in Neuro Oncol (2018)

P11.28 Alteration of blood brain barrier (BBB) permeability by Tumor Treating Fields (TTFields) in vivo

di Keßler, A F, Salvador, E, Domröse, D, Burek, M, Tempel Brami, C, Voloshin Sela, T, Giladi, M, Ernestus, R, Löhr, M, Förster, C, Hagemann, C
Pubblicato in Neuro Oncol (2019)

P01.050 Circulating MACC1 transcript plasma levels in glioblastoma patients segregate together with prognostic markers and treatment response

di Hagemann, C, Neuhaus, N, Dahlmann, M, Kessler, A F, Kobelt, D, Herrmann, P, Eyrich, M, Freitag, B, Freitag, B, Linsenmann, T, Monoranu, C M, Ernestus, R, Löhr, M, Stein, U
Pubblicato in Neuro Oncol (2018)